Retatrutide

Key Benefits#

• ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
• Superior to both semaglutide and tirzepatide in early trial comparisons
• Triple receptor mechanism addresses multiple obesity pathways
• Significant reduction in liver fat (MASH/NAFLD indication being studied)
• Improved cardiovascular and metabolic markers
• Once-weekly dosing
• Potential for greatest weight loss of any currently investigated compound

Mechanism of Action#

Retatrutide adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism of tirzepatide. Glucagon receptor activation in the liver increases energy expenditure, promotes hepatic fat oxidation, and reduces liver fat (NAFLD/MASH). The triple mechanism synergistically addresses all major drivers of obesity: appetite (GLP-1, GIP), energy expenditure (glucagon), and fat metabolism (all three). This explains the superior weight loss vs dual agonists.

Dosing Protocols#

Side Effects#

• Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
• Diarrhea
• Constipation
• Heart rate increase (from glucagon receptor agonism)
• Injection site reactions
• Potential gallbladder effects

Contraindications#

Personal or family history of medullary thyroid cancer or MEN2 syndrome. Pregnancy or breastfeeding. Not FDA approved — research/investigational use only.

Storage#

Refrigerate (2–8°C). Protect from light. Per manufacturer handling guidelines.

Featured In Stacks#

1. 1.
   Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models

   Briand F, Le Cudennec C, Grasset E, Breyner N, Bigot C, Dillard P et al. · Obesity (Silver Spring, Md.) · 2026PubMed Verified

2. 2.
   Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison

   Hitaka K, Sugawara T, Matsumoto M, Nio Y · International journal of obesity (2005) · 2026PubMed Verified

3. 3.
   Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis

   Chan ZH, Omar AS, Gill K, Volucke G, Azhar MM, Haleem SM et al. · Cardiology in review · 2026PubMed Verified

4. 4.
   Development of the Weight and Emotions Scale (WES)

   Kanu C, Kimel M, Goetz I, Neff LM, Boye KS, Stefan M et al. · Obesity science & practice · 2026PubMed Verified

5. 5.
   Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials

   Zhang Y, Zhang C, Gong X, Cheng P, Fu H, Diao L et al. · European journal of medical research · 2026Meta-AnalysisPubMed Verified

6. 6.
   Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders

   Alavi SE, Boshrouyeh R, Raza A, Ebrahimi Shahmabadi H · European journal of medicinal chemistry · 2026ReviewPubMed Verified

7. 7.
   The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

   Ganamurali N, Sabarathinam S · Clinical pharmacology in drug development · 2026ReviewPubMed Verified

8. 8.
   Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis

   Pallavi K, Chandra A, Kumar K, Martand K, Sahu SS, Mohan L et al. · Maedica · 2025ReviewPubMed Verified

9. 9.
   IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

   Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN · Pharmacological research · 2026ReviewPubMed Verified

10. 10.
    Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies

    Raza SS, Zakir Z, Hashmat A, Awan SK, Varrassi G · Cureus · 2025ReviewPubMed Verified

11. 11.
    Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed

    Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, Navarro-González JF · Journal of clinical medicine · 2025ReviewPubMed Verified

12. 12.
    Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon

    Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN et al. · Journal of obesity · 2025ReviewPubMed Verified

13. 13.
    Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review

    Takrori E, Peshin S, Singal S · Medicina (Kaunas, Lithuania) · 2025Meta-AnalysisPubMed Verified

14. 14.
    Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders

    Cho YK, Jung CH · Clinical and molecular hepatology · 2025PubMed Verified

15. 15.
    Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial

    Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M et al. · Obesity pillars · 2025PubMed Verified

16. 16.
    Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity

    Kanu C, Clucas C, Skalicky A, Samuelson A, Goetz I, Neff LM et al. · Advances in therapy · 2026PubMed Verified

17. 17.
    Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease

    Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I et al. · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025PubMed Verified

18. 18.
    The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review

    Hudanich M, Smith SN, Marino A, Riskin SI · Cureus · 2025ReviewPubMed Verified

19. 19.
    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

20. 20.
    Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge

    Viebahn GK, Khurana A, Freund L, Chilin-Fuentes D, Jepsen K, Rosenthal SB et al. · American journal of physiology. Gastrointestinal and liver physiology · 2025PubMed Verified

21. 21.
    Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity

    Son JW, le Roux CW, Blüher M, Nauck MA, Lim S · Endocrine reviews · 2025PubMed Verified

22. 22.
    Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions

    Neff GW · Diabetes, obesity & metabolism · 2025ReviewPubMed Verified

23. 23.
    Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

    Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS et al. · World journal of gastroenterology · 2025ReviewPubMed Verified

24. 24.
    Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

    Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B et al. · Endocrinology, diabetes & metabolism · 2025Meta-AnalysisPubMed Verified

25. 25.
    Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs

    Cigrovski Berkovic M, Ruzic L, Cigrovski V, Strollo F · World journal of diabetes · 2025ReviewPubMed Verified

26. 26.
    Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects

    Wang S, Liu Y, Yan Z, Huang X, Liao Y, Tang C et al. · Journal of medicinal chemistry · 2025PubMed Verified

27. 27.
    Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare

    Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM · World journal of cardiology · 2025ReviewPubMed Verified

28. 28.
    Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

    Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J et al. · Diabetes, obesity & metabolism · 2025RCTPubMed Verified

29. 29.
    Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis

    Basile C, Merolla A, Mancusi C, De Luca C, Fucile I, Canonico ME et al. · European journal of preventive cardiology · 2025PubMed Verified

30. 30.
    Weight management treatment in obesity

    Rubio-Herrera MA, Mera-Carreiro S · Medicina clinica · 2025ReviewPubMed Verified

31. 31.
    Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies

    Ullah MI, Tamanna S · Medicines (Basel, Switzerland) · 2025ReviewPubMed Verified

32. 32.
    Triple Agonism Based Therapies for Obesity

    Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D · Current cardiovascular risk reports · 2025ReviewPubMed Verified

33. 33.
    Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight

    Kanu C, Wu Q, Poon JL, Goetz I, Perez-Nieves M, Boye K et al. · Diabetes, obesity & metabolism · 2025PubMed Verified

34. 34.
    Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations

    Anderson SL · Drugs in context · 2025ReviewPubMed Verified

35. 35.
    Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies

    Abburi K, Melson E, Miras AD, Papamargaritis D · Panminerva medica · 2025ReviewPubMed Verified

36. 36.
    Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials

    Misra S, Narayan RK, Kaur M · Journal of basic and clinical physiology and pharmacology · 2025Meta-AnalysisPubMed Verified

37. 37.
    Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids

    Wen Y, Lemen D, Lin Y, Chen YQ, Regmi A, Roell WC et al. · Diabetes, obesity & metabolism · 2025Clinical TrialPubMed Verified

38. 38.
    Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats

    Windram M, Lovelock DF, Carew JM, Krieman CG, Hendershot CS, Besheer J · Psychopharmacology · 2025PubMed Verified

39. 39.
    Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA

    Sinha B, Ghosal S · Obesity (Silver Spring, Md.) · 2025Meta-AnalysisPubMed Verified

40. 40.
    The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity

    Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A et al. · Kidney international reports · 2025PubMed Verified

41. 41.
    Inotropic effects of retatrutide in isolated human atrial preparations

    Neumann J, Ahlrep U, Hofmann B, Gergs U · Naunyn-Schmiedeberg's archives of pharmacology · 2026PubMed Verified

42. 42.
    Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

    Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C et al. · The lancet. Diabetes & endocrinology · 2025RCTPubMed Verified

43. 43.
    Incretin-based therapies for the treatment of obesity-related diseases

    Caruso I, Cignarelli A, Sorice GP, Perrini S, Giorgino F · npj metabolic health and disease · 2024ReviewPubMed Verified

44. 44.
    Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes

    Olowo-Oribi BA, Salway RJ · Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025ReviewPubMed Verified

45. 45.
    Retatrutide-A Game Changer in Obesity Pharmacotherapy

    Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K · Biomolecules · 2025ReviewPubMed Verified

46. 46.
    Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease

    Rodriguez N, Hartmann P · Pharmacological reviews · 2025ReviewPubMed Verified

47. 47.
    Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

    Wang Y, Zhou Y, Wang Z, Ni Y, Prud'homme GJ, Wang Q · The Journal of clinical endocrinology and metabolism · 2025Meta-AnalysisPubMed Verified

48. 48.
    Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis

    Yan K, Yu H, Blaise B · Acta diabetologica · 2025Meta-AnalysisPubMed Verified

49. 49.
    Contractile effects of retatrutide in isolated mouse atrial preparations

    Neumann J, Ahlrep U, Hofmann B, Gergs U · Naunyn-Schmiedeberg's archives of pharmacology · 2025PubMed Verified

50. 50.
    Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

    Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y et al. · Proceedings (Baylor University. Medical Center) · 2025ReviewPubMed Verified